Allergan may be more effective in its defense against a hostile takeover bid by Valeant Pharmaceuticals if it makes a purchase of its own, an analyst says.» Read More
NEW YORK, April 23- Ever since they were badly burned in the 2008-2009 stock and bond debacle, investors have been pouring money into so-called "alternative" mutual funds, often at the behest of financial advisers who say those funds will protect them from the fire next time.
Bill Ackman tells CNBC that his losses from betting against Herbalife have been "more than cut in half" based on the recent downturn of the company's stock.
Maybe it was the martini that helped Carl Icahn publicly support longtime nemesis Bill Ackman, but he still calls Marty Lipton "dead wrong."
Stocks of SunEdison and Conn's jumped Tuesday on news that David Einhorn's Greenlight Capital had opened new positions in them.
Bill Ackman also tells CNBC that Allergan's poison-pill defense doesn't make his takeover bid more difficult.
William Ackman, Pershing Square Capital Management, explains how his partnership with Valeant is structured. And J. Michael Pearson, Valeant chairman & CEO, discusses why he partnered with Ackman instead of pursing Allergan alone. Creating shareholder value is our job, says Pearson.
William Ackman, Pershing Square Capital Management, explains why he is helping Valeant buy Allergan.
J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, weighs in on news that Allergan has adopted a "poison pill" defense strategy. Also Pearson shares his thoughts on adding some of Allergan's notable cosmetic products like Botox and Restasis to its growing arsenal.
J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, explains why he decided to pursue Allergan and shares his R&D business model, with CNBC's Kate Kelly. This year we are launching 19 products in the United States, says Pearson.
William Ackman, Pershing Square Capital Management, explains why he decided to team up with Valeant Pharmaceuticals to make a play for Allergan.
April 22- David Einhorn's Greenlight Capital Inc closed the firm's money-losing short position in Chipotle Mexican Grill Inc, the $10 billion hedge fund said in a letter to clients on Tuesday, and the firm has started shorting a group of momentum stocks that he did not identify.
Hedge fund manager Bill Ackman promised to pay a disgruntled ex-Herbalife executive as much as $3.60 million over the next 10 years, a report said.
Walgreen's pending acquisition of Alliance Boots can mean lower taxes and a better company, according to activist investor Barry Rosenstein.
Greenlight Capital supports IEX and holds a stake in it.
Virtually every Pershing Square Capital investment appears to have made money this year.
Sandy Villere, Villere Funds, shares his thoughts on Greenlight Capital's new stake in Conn's.
More than half the revenue from Botox comes from therapeutic, not cosmetic, use. And its potential is helping to make Allergan an attractive target.
In a letter to investors David Einhorn of Greenlight Capital said he's witnessing a tech bubble and has bet against a number of momentum stocks.
Option traders were either lucky or knew something in advance of the Allergan news. Fast Money trader Jon Najarian, provides insight.
CNBC's Kate Kelly has the latest details on Bill Ackman and Valeant's bid for Allergan.
Get the best of CNBC in your inbox